Positron Emission Tomography for Meningioma

Phase-Based Progress Estimates
MeningiomaPositron Emission Tomography - Procedure
All Sexes
What conditions do you have?

Study Summary

This trial uses Gallium Ga 68-DOTATATE to see if it can help predict tumor growth in patients with meningiomas.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Up to 1 year

Up to 1 year
Imaging with Gallium Ga 68-DOTATATE
Metabolic response to radiation therapy

Trial Safety

Safety Progress

1 of 3

Side Effects for

18F-fluoromethylcholine PET/CT
3%death within 30 days
This histogram enumerates side effects from a completed 2018 Phase 2 trial (NCT01395030) in the 18F-fluoromethylcholine PET/CT ARM group. Side effects include: death within 30 days with 3%.

Trial Design

1 Treatment Group

Diagnostic (gallium Ga 68-DOTATATE PET/CT)
1 of 1

Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: Positron Emission Tomography · No Placebo Group · Phase 1

Diagnostic (gallium Ga 68-DOTATATE PET/CT)Experimental Group · 3 Interventions: Computed Tomography, Positron Emission Tomography, Gallium Ga 68-DOTATATE · Intervention Types: Procedure, Procedure, Radiation
First Studied
Drug Approval Stage
How many patients have taken this drug
Computed Tomography
Completed Phase 2
Positron Emission Tomography
Completed Phase 2

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,093 Previous Clinical Trials
41,143,308 Total Patients Enrolled
44 Trials studying Meningioma
4,008 Patients Enrolled for Meningioma
M.D. Anderson Cancer CenterLead Sponsor
2,808 Previous Clinical Trials
1,790,479 Total Patients Enrolled
2 Trials studying Meningioma
20 Patients Enrolled for Meningioma
Jason M JohnsonPrincipal InvestigatorM.D. Anderson Cancer Center
6 Previous Clinical Trials
216 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a meningioma with at least 10 mm measurable residual disease.
You must be between the ages of 18 and 65 years old.